Loading
Stryker Corp Stock: price and insider trades · United States
Stryker Corp: what insiders have been doing
Every trade that managers of Stryker Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Portage, United States. It was founded in 1946. The last twelve months, up to 18 October 2026, brought 69 filings signed by 15 insiders.
Only sales appear on the open market, 31 sales in all totalling €113.8M, filed by 5 insiders. Stryker Ronda e filed the largest sale, €38.2M, on 20 August 2026, which represents 0.042% of the company's market value.
Across the 5,813 companies tracked on its exchange, the median is 19 filings; at 69 filings, this issuer sits above that mark. Over the whole record (from 2016), the tally stands at no purchases and 97 sales. The 10-K for the year ended 31 December 2025 shows 25.12 bn USD of revenue and 3.25 bn USD of net income.
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
354
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€256M
97 ops. · all time
Who traded when
BuySaleRonda E. Stryker26 sales
Fletcher Robert S7 sales
Berry William E Jr1 sale
Dylan Bram Crotty1 sale
King Debra1 sale
Menon Viju1 sale
+1 other insider
Analyst consensus: bullish or bearish?
Analysts rate Stryker Corp Buy (bullish), based on 26 analysts. Average price target: US$362.62.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,213 of 24,148 companies
57.4
score / 100
Value44
Quality70
FCF yld3.8%
Earn yld2.9%
EV/EBITDA20.3x
ROE17%
Gross mgn64%
Net mgn13%
Debt/EBITDA2.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$293.23
Analyst consensus
26 analystsBuy
US$298.00Target US$362.62(+24%)US$465.00
Income statement
RevenueUS$25.1B
Gross profitUS$16.1B64% margin
EBITDAUS$6.3B25% margin
Net incomeUS$3.2B14.4% margin
Valuation
PER (trailing)29.3x
PER (forward)17.6x
P/Book4.7x
Beta0.78
Balance sheet & cash
Market capUS$112.5B
Total debtUS$15.9B
Free Cash FlowUS$4.3B
Debt / Equity64%
Profitability & ownership
ROE16.5%
ROA8.2%
% insiders5.4%
% institutions82.9%
Last declaration on 28 September 2026
Declarations354 total
109 shares0Common StockSEC:0002063939-26-000004:0
1,776.804 shares0Common StockSEC:0002063939-26-000003:0
962 shares0Common StockSEC:0002063939-26-000003:1
441 shares@ US$328.6050.0001% mcap53.7% of flowCommon StockSEC:0002104636-26-000005:0
16,612 shares@ US$340.7060.0053% mcap2.1% of flowCommon StockSEC:0001242914-26-000010:16
2,239 shares@ US$331.7420.0007% mcap0.3% of flowCommon StockSEC:0001242914-26-000010:0
2,920 shares@ US$332.6940.0009% mcap0.4% of flowCommon StockSEC:0001242914-26-000010:1
8,404 shares@ US$333.8250.0026% mcap1.0% of flowCommon StockSEC:0001242914-26-000010:2
25,536 shares@ US$334.9450.0080% mcap3.2% of flowCommon StockSEC:0001242914-26-000010:3
131,752 shares@ US$335.6420.042% mcap16.4% of flowCommon StockSEC:0001242914-26-000010:4
109,425 shares@ US$336.4330.035% mcap13.7% of flowCommon StockSEC:0001242914-26-000010:5
16,243 shares@ US$337.6290.0052% mcap2.0% of flowCommon StockSEC:0001242914-26-000010:6
3,481 shares@ US$338.4980.0011% mcap0.4% of flowCommon StockSEC:0001242914-26-000010:7
40 shares@ US$331.8050.0000% mcap0.0% of flowCommon StockSEC:0001242914-26-000010:8
440 shares@ US$333.1770.0001% mcap0.1% of flowCommon StockSEC:0001242914-26-000010:9
200 shares@ US$333.9310.0001% mcap0.0% of flowCommon StockSEC:0001242914-26-000010:10
80 shares@ US$335.0550.0000% mcap0.0% of flowCommon StockSEC:0001242914-26-000010:11
320 shares@ US$336.7930.0001% mcap0.0% of flowCommon StockSEC:0001242914-26-000010:12
2,308 shares@ US$337.9820.0007% mcap0.3% of flowCommon StockSEC:0001242914-26-000010:13
11,257 shares@ US$338.8990.0036% mcap1.4% of flowCommon StockSEC:0001242914-26-000010:14
10,812 shares@ US$339.710.0035% mcap1.4% of flowCommon StockSEC:0001242914-26-000010:15
3,274 shares@ US$341.8390.0011% mcap0.4% of flowCommon StockSEC:0001242914-26-000010:17
3,852 shares@ US$342.7970.0012% mcap0.5% of flowCommon StockSEC:0001242914-26-000010:18
805 shares@ US$343.4720.0003% mcap0.1% of flowCommon StockSEC:0001242914-26-000010:19
826 shares@ US$336.30270.0003% mcap100.0% of flowCommonSEC144:0001969223-26-000921
25 of 354 declarations
About Stryker Corp
Stryker Corp. (ticker: SYK) is a leading U.S. healthcare company listed on the NYSE. Headquartered in Portage, Michigan, United States, the company is one of the major global players in medical technologies. Its roots go back to 1941, when Homer Stryker began developing and commercializing inventions inspired by his orthopedic practice. That origin still shapes the company’s identity today: product innovation, close collaboration with clinicians, and a disciplined acquisition strategy used to broaden its portfolio. ([stryker.com](https://www.stryker.com/us/en/about.html?utm_source=openai))
Stryker operates through three core reporting areas: MedSurg, Neurotechnology, and Orthopaedics. MedSurg includes surgical equipment, endoscopy, patient-handling and patient-safety technologies, and selected hospital care products. Neurotechnology covers neurosurgical and neurovascular solutions, as well as certain spine- and pain-related technologies. Orthopaedics comprises implants and solutions for hip, knee, shoulder, trauma, and extremities procedures. This structure gives Stryker a diversified exposure across hospital capital spending, elective surgery, and higher-value specialty procedures. ([stryker.com](https://www.stryker.com/us/en/about.html?utm_source=openai))
Read moreShow less
From a competitive standpoint, Stryker is widely regarded as a top-tier medical device leader, with strong brand recognition among hospitals and surgeons. Its positioning is built on clinical quality, a robust commercial footprint, and the ability to offer broad procedural platforms that combine instruments, implants, consumables, and adjacent digital solutions. The company has a meaningful global footprint, with revenue-generating operations across the United States, Europe, the Middle East and Africa, Asia Pacific, and other foreign markets, including Canada and Latin America. ([sec.gov](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/syk-20241231.htm?utm_source=openai))
Its product set spans surgical systems, hospital equipment, orthopedic implants, and newer solutions in thrombectomy, intravascular lithotripsy, and foot-and-ankle surgery. Recent corporate developments highlight an active M&A agenda and a continued push into faster-growing vascular categories: Stryker completed its acquisition of Inari Medical in February 2025, then used that platform to launch new products such as InThrill and Artix. In 2026, it announced and completed the acquisition of Amplitude Vascular Systems to strengthen its peripheral vascular portfolio. The company also secured FDA clearances for products such as OptaBlate BVN and Incompass, underscoring an active innovation pipeline. ([investors.stryker.com](https://investors.stryker.com/press-releases/news-details/2025/Stryker-completes-acquisition-of-Inari-Medical-Inc.-providing-entry-into-the-high-growth-peripheral-vascular-segment/default.aspx?utm_source=openai))
For investors, Stryker remains a high-quality U.S. healthcare name: defensive characteristics, recurring innovation, a large installed base, and consistent execution. The main considerations are exposure to hospital spending cycles, intense competition, and operational or cybersecurity risks given the scale and complexity of its technology-enabled business. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/01/28/3016762/0/en/Stryker-reports-2024-operating-results-and-2025-outlook.html?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
